A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
12/2011
12/08/2011	WO2011151341A1 Lactadherin-derived peptides as antiviral agents
12/08/2011	WO2011151333A1 Papillomavirus l2 c-terminal peptides for vaccination
12/08/2011	WO2011151078A1 Novel interferon-alpha-producing bone marrow dendritic cells
12/08/2011	WO2011151076A2 MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS
12/08/2011	WO2011150745A1 Mycobacterium tuberculosis ag85ab chimeric gene vaccine, its preparation method and application
12/08/2011	WO2011150566A1 Novel dna vaccine adjuvant
12/08/2011	WO2011150454A1 ANTIBODIES DIRECTED TO THE UNPROCESSED RECEPTOR TYROSINE KINASE c-MET
12/08/2011	WO2011130627A3 Chimpanzee adenoviral vector-based filovirus vaccines
12/08/2011	WO2011103599A9 Epithelial membrane protein 2 (emp2) binding reagents and their therapeutic uses in ocular diseases
12/08/2011	WO2011103028A3 Compositions and methods for inhibiting mmset
12/08/2011	WO2011102999A3 Spink1 targeted therapy
12/08/2011	WO2011100453A3 Compositions and methods for the treatment of cardiac and vascular disease
12/08/2011	WO2011097527A9 Immunoprotection of therapeutic moieties using enhanced fc regions
12/08/2011	WO2011041350A3 Xenotropic mulv-related virus (xmrv) compositions and methods of use
12/08/2011	WO2010072741A9 TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREFOR
12/08/2011	US20110301339 Novel inhibitors of vascular endothelial growth factor activity, their uses and processes for their production
12/08/2011	US20110301338 Novel inhibitors of vascular endothelial growth factor activity, their uses and processes for their production
12/08/2011	US20110301337 Novel inhibitors of vascular endothelial growth factor activity, their uses and processes for their production
12/08/2011	US20110300578 Novel inhibitors of vascular endothelial growth factor activity, their uses and processes for their production
12/08/2011	US20110300577 Novel inhibitors of vascular endothelial growth factor activity, their uses and processes for their production
12/08/2011	US20110300226 Peptide particle formulation
12/08/2011	US20110300223 Immunogenic composition
12/08/2011	US20110300219 Nanostructures for drug delivery
12/08/2011	US20110300206 Vaccines against chlamydial infection
12/08/2011	US20110300205 Self replicating rna molecules and uses thereof
12/08/2011	US20110300186 Functionalized Nano- and Micro-materials for Medical Therapies
12/08/2011	US20110300185 Immunogenic escherichia coli heat stable enterotoxin
12/08/2011	US20110300181 Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
12/08/2011	US20110300180 plant-derived vaccines against respiratory syncytial virus
12/08/2011	US20110300179 Novel Compositions and Uses Thereof
12/08/2011	US20110300178 Hpv types and variants associated with cervical cancer and the uses thereof
12/08/2011	US20110300177 Triterpene saponins, methods of synthesis, and uses thereof
12/08/2011	US20110300176 Microorganisms for therapy
12/08/2011	US20110300174 Conjugates for the prevention or treatment of nicotine addiction
12/08/2011	US20110300173 Capsule composition for use as immunogen against Campylobacter jejuni
12/08/2011	US20110300172 Fusion proteins and related compositions, methods and systems for treatment and/or prevention of atherosclerosis
12/08/2011	US20110300171 Factor h binding protein immunogens
12/08/2011	US20110300170 Hcv vaccines
12/08/2011	US20110300169 Pharmaceutical composition comprising an antigen
12/08/2011	US20110300168 Compositions and methods for inducing an immune response against influenza antigens
12/08/2011	US20110300166 Vaccine Compositions for Inducing Immune Responses Against Components of Drusen
12/08/2011	US20110300164 Immunostimulatory dna:rna oligonucleotides
12/08/2011	US20110300163 IgE CH3 Peptide Vaccine
12/08/2011	US20110300161 Methods for the Treatment and the Prognostic Assessment of Malignant Pleural Mesothelioma
12/08/2011	US20110300160 Sulfation of wnt pathway proteins
12/08/2011	US20110300159 Sulfonated Sclerostin, antibodies, epitopes and methods for identification and use therefor
12/08/2011	US20110300158 Anti-serum albumin binding variants
12/08/2011	US20110300157 Metalloproteinase 9 and metalloproteinase 2 binding proteins
12/08/2011	US20110300156 Human antibodies against tissue factor
12/08/2011	US20110300155 Modulating xrn2
12/08/2011	US20110300154 Treatment of airway hyperreactivity
12/08/2011	US20110300153 Antibody produced using ostrich and method for production thereof
12/08/2011	US20110300152 Compositions and methods for modulating cell-cell fusion via intermediate-conductance calcium-activated potassium channels
12/08/2011	US20110300151 Uses and compositions for treatment of hidradenitis suppurativa (hs)
12/08/2011	US20110300150 Compositions and methods for treatment of autoimmune and other disease
12/08/2011	US20110300149 Ljungan virus
12/08/2011	US20110300148 Il-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases
12/08/2011	US20110300147 Inhibiting tumor cell invasion, metastasis and angiogenesis
12/08/2011	US20110300146 Anti-cmet antagonists
12/08/2011	US20110300145 Interferon Alpha Antibodies And Their Uses
12/08/2011	US20110300144 Methods and compositions for diagnosis and treatment of cancer
12/08/2011	US20110300143 Prenatal enzyme replacement therapy
12/08/2011	US20110300142 Use of zeburaline for the treatment of autoimmune diseases or immune rejection of transplants
12/08/2011	US20110300141 Novel Alphabeta-Binding protein and its peptide derivatives and uses thereof
12/08/2011	US20110300140 Antigen binding polypeptides
12/08/2011	US20110300139 Generation, expression and characterization of the humanized k33n monoclonal antibody
12/08/2011	US20110300138 Human anti tshr antibodies
12/08/2011	US20110300137 Use of lumefantrine and related compounds in the treatment of cancer
12/08/2011	US20110300136 Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
12/08/2011	US20110300135 Method and formulation for reducing aggregation of a macromolecule under physiological conditions
12/08/2011	US20110300134 Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof
12/08/2011	US20110300133 Chimeric and humanized antibodies to alpha5beta1 integrin that modulate angiogenesis
12/08/2011	US20110300132 4-aminoquinazoline prodrugs
12/08/2011	US20110300131 Detection and treatment of pancreatic, ovarian and other cancers
12/08/2011	US20110300130 Impaired wound healing compositions and treatments
12/08/2011	US20110300129 Systems and methods for enhancing vaccine efficacy
12/08/2011	US20110300128 Use of foxp2 as a marker for abnormal lymphocytes and as a target for therapy of disorders associated with abnormal lymphocytes
12/08/2011	US20110300127 Drug-containing composition
12/08/2011	US20110300104 Hepatitis c virus inhibitors
12/08/2011	US20110300101 Methods for treating viral infection using IL-28 and IL-29 Cysteine mutants
12/08/2011	US20110300098 Methods of treating cancer using il-21 and monoclonal antibody therapy
12/08/2011	US20110300077 Human Anti-Alpha-Synuclein Antibodies
12/08/2011	US20110300068 Agent for prophylaxis or treatment of cancer
12/08/2011	US20110300066 Combination Therapy With Anti-CD74 Antibodies Provides Enhanced Toxicity to Malignancies, Autoimmune Disease and Other Diseases
12/08/2011	CA2805270A1 Treatment of inflammatory disorders
12/08/2011	CA2801917A1 Uses and compositions for treatment of hidradenitis suppurativa (hs)
12/08/2011	CA2801802A1 Humanised antigen binding proteins to myostatin6
12/08/2011	CA2801585A1 Peptide particle formulation
12/08/2011	CA2801554A1 Nasal immunization
12/08/2011	CA2801509A1 Treatment drug for autoimmune diseases and allergic diseases
12/08/2011	CA2801266A1 Oral vaccine comprising an antigen and a toll-like receptor agonist
12/08/2011	CA2801264A1 Novel anti-cmet antibody
12/08/2011	CA2801184A1 Peripheral blood sparc binding antibodies and uses thereof
12/08/2011	CA2801151A1 Concentration of vaccine antigens with lyophilization
12/08/2011	CA2801149A1 Concentration of vaccine antigens without lyophilization
12/08/2011	CA2801125A1 Pharmaceutical product comprising mite allergen extract(s) and a method for the manufacture thereof
12/08/2011	CA2801038A1 Lactadherin-derived peptides as antiviral agents
12/08/2011	CA2800882A1 Conjugates for the prevention or treatment of nicotine addiction
12/08/2011	CA2800844A1 Novel interferon-alpha-producing bone marrow dendritic cells
12/08/2011	CA2800824A1 Novel modified live-attenuated vaccines (mlv) and subunit vaccines created by dna shuffling against porcine reproductive and respiratory syndrome virus (prrsv)

1 ... 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 ... 1823